Company profile
IRONWOOD PHARMACEUTICALS INC
NASDAQ:IRWDBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ALLOPURINOL | approved | — | 0 | — |
| COLESEVELAM HYDROCHLORIDE | approved | — | 5 | approved |
| LESINURAD | approved | — | 1 | approved |
| RECANACLOTIDE | phase2 | — | 2 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (25)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05740007 | phase2 | terminated | 2023-03-28 | 2025-01-23 | Ironwood Pharmaceuticals, Inc. | A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome |
| NCT03226899 | phase4 | terminated | 2017-07-19 | 2019-02-25 | Ironwood Pharmaceuticals, Inc. | A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment |
| NCT03931785 | phase2 | completed | 2019-05-01 | 2020-02-26 | Ironwood Pharmaceuticals, Inc. | A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome |
| NCT05362695 | phase1 | completed | 2022-05-17 | 2022-06-30 | Ironwood Pharmaceuticals, Inc. | A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects |
| NCT05188261 | phase1 | completed | 2022-01-18 | 2022-03-09 | Ironwood Pharmaceuticals, Inc. | A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 207988 | NDA | IRONWOOD PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 209203 | NDA | IRONWOOD PHARMACEUTICALS INC | ||||
Loading… | ||||||